The GEFS+ Spectrum: Identifying Your Child's Path
At a Glance
GEFS+ is a variable epilepsy spectrum: children may have febrile seizures that continue after age 6 and may also have seizures without fever. An SCN1A variant alone does not diagnose Dravet syndrome; seizure patterns, age at onset, duration, and development over time guide diagnosis.
When a child is diagnosed with Genetic Epilepsy with Febrile Seizures Plus (GEFS+), it is important to understand that the diagnosis is a “spectrum.” This means it covers a range of experiences, from very mild childhood seizures to more complex forms of epilepsy [1][2].
The Layers of the GEFS+ Spectrum
Doctors use specific terms to describe where a child fits within this spectrum based on when and how their seizures occur.
- Typical Febrile Seizures: These are common in early childhood, usually starting between 6 months and 5 years of age [3]. Typical febrile seizures are very common in the general public and usually occur outside of GEFS+. Most children outgrow these by age 5 or 6 [4].
- Febrile Seizures Plus (FS+): This is the hallmark of GEFS+. In this phenotype, a child may continue to have febrile seizures well past the age of 6 [5]. They may also experience different types of seizures, such as absence seizures (staring spells) or focal seizures (affecting one part of the brain) [6][1].
- Afebrile Seizures: Some children in the GEFS+ spectrum will have seizures that occur without a fever [6]. These can include generalized tonic-clonic seizures (stiffening and jerking) or myoclonic seizures (brief, lightning-like jerks) [1][2].
GEFS+ vs. Dravet Syndrome: Understanding the Difference
Because many children with GEFS+ and almost all children with Dravet syndrome can have a mutation in the SCN1A gene, parents often worry that their child’s diagnosis will progress to the more severe condition [7][8]. While they share a genetic link, they follow very different paths. GEFS+ is generally much milder, and most children lead typical lives with normal cognitive development [9][10].
Dravet syndrome is a severe developmental and epileptic encephalopathy. Doctors look for specific “clues” to distinguish it from the milder GEFS+ phenotypes [11][12].
Clinical Clues for Dravet Syndrome
While every child is different, the following signs are much more common in Dravet syndrome than in GEFS+. Their presence should prompt a timely reassessment by a specialist:
- Early Onset: Seizures in Dravet syndrome typically begin very early, often before 6 months of age, though they can start later [13].
- Prolonged Seizures: The first seizure in Dravet syndrome is often significantly prolonged. While formal research defines status epilepticus as lasting 15 to 30 minutes [12][13], for practical safety at home, any convulsive seizure lasting 5 minutes or more requires immediate emergency treatment.
- One-Sided Seizures: Known as hemiclonic seizures, these involve jerking on only one side of the body. This is a characteristic feature of Dravet syndrome and is rarely seen in milder GEFS+ [12][14].
- Developmental Changes: Children with Dravet syndrome usually meet their milestones normally in the first year [12]. However, after the first or second year, development may slow down or plateau (stagnation), or the child may lose previously gained skills (regression) [7][15]. In GEFS+, severe regression is atypical [10].
- Multiple Seizure Types: Over time, children with Dravet syndrome often develop many different types of seizures, including myoclonic and atypical absence seizures, which become frequent and difficult to treat with standard medications [16][17].
Monitoring the Trajectory
It is important to remember that a genetic test result (like finding an SCN1A variant) does not automatically mean a child has Dravet syndrome [7]. Diagnosis is based on the “phenotype”—the actual symptoms and patterns the child shows over time [2][11]. By tracking the age of onset, the length and type of seizures, and developmental progress, your care team can accurately determine where your child sits on the spectrum and provide the most appropriate support [12].
Common questions in this guide
What does GEFS+ mean for a child with febrile seizures?
How can doctors tell GEFS+ apart from Dravet syndrome?
Does an SCN1A mutation mean that my child has Dravet syndrome?
Which seizure signs should prompt urgent medical attention or reassessment?
Can a child with GEFS+ have seizures without a fever?
Questions For You
Answer a question to get research tailored to you. Your answers are private.
Get notified when new evidence is published on Genetic epilepsy with febrile seizure plus.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.How do you distinguish between my child's current seizures and the specific clues for Dravet syndrome?
- 2.Given my child's age of onset and seizure types, which phenotype within the GEFS+ spectrum is the best fit?
- 3.Since SCN1A mutations can lead to both GEFS+ and Dravet syndrome, what clinical features are you monitoring to track my child's trajectory?
- 4.Is my child's current developmental progress typical for their age, and when should we perform a formal developmental assessment?
- 5.What is the likelihood that my child will develop afebrile seizures if they only have febrile seizures now?
References
References (17)
- 1
Genetic epilepsy with febrile seizures plus: Refining the spectrum.
Zhang YH, Burgess R, Malone JP, et al.
Neurology 2017; (89(12)):1210-1219 doi:10.1212/WNL.0000000000004384.
PMID: 28842445 - 2
Clinical and genetics spectrum of 392 Chinese patients with genetic epilepsy with febrile seizures plus.
Chen S, Quan Y, Yin F, Peng J
Journal of neurology 2025; (273(1)):18.
PMID: 41366559 - 3
Febrile seizures and genetic epilepsy with febrile seizures plus (GEFS+).
Camfield P, Camfield C
Epileptic disorders : international epilepsy journal with videotape 2015; (17(2)):124-33 doi:10.1684/epd.2015.0737.
PMID: 25917466 - 4
Febrile seizures: an overview.
Leung AK, Hon KL, Leung TN
Drugs in context 2018; (7()):212536 doi:10.7573/dic.212536.
PMID: 30038660 - 5
Genetic literacy series: genetic epilepsy with febrile seizures plus.
Myers KA, Scheffer IE, Berkovic SF,
Epileptic disorders : international epilepsy journal with videotape 2018; (20(4)):232-238 doi:10.1684/epd.2018.0985.
PMID: 30078767 - 6
GABRG2 mutations in genetic epilepsy with febrile seizures plus: structure, roles, and molecular genetics.
Li X, Guo S, Sun Y, et al.
Journal of translational medicine 2024; (22(1)):767 doi:10.1186/s12967-024-05387-1.
PMID: 39143639 - 7
Development and Validation of a Prediction Model for Early Diagnosis of SCN1A-Related Epilepsies.
Brunklaus A, Pérez-Palma E, Ghanty I, et al.
Neurology 2022; (98(11)):e1163-e1174 doi:10.1212/WNL.0000000000200028.
PMID: 35074891 - 8
Dravet syndrome as part of the clinical and genetic spectrum of sodium channel epilepsies and encephalopathies.
Mei D, Cetica V, Marini C, Guerrini R
Epilepsia 2019; (60 Suppl 3()):S2-S7 doi:10.1111/epi.16054.
PMID: 31904125 - 9
Outcomes and comorbidities of SCN1A-related seizure disorders.
de Lange IM, Gunning B, Sonsma ACM, et al.
Epilepsy & behavior : E&B 2019; (90()):252-259 doi:10.1016/j.yebeh.2018.09.041.
PMID: 30527252 - 10
Understanding neurodevelopmental trajectories and behavioral profiles in SCN1A-related epilepsy syndromes.
Postma A, Minderhoud CA, Otte WM, et al.
Epilepsy & behavior : E&B 2024; (154()):109726 doi:10.1016/j.yebeh.2024.109726.
PMID: 38513571 - 11
Optimizing the Diagnosis and Management of Dravet Syndrome: Recommendations From a North American Consensus Panel.
Wirrell EC, Laux L, Donner E, et al.
Pediatric neurology 2017; (68()):18-34.e3 doi:10.1016/j.pediatrneurol.2017.01.025.
PMID: 28284397 - 12
Defining Dravet syndrome: An essential pre-requisite for precision medicine trials.
Li W, Schneider AL, Scheffer IE
Epilepsia 2021; (62(9)):2205-2217 doi:10.1111/epi.17015.
PMID: 34338318 - 13
Genotype-phenotype associations in 1018 individuals with SCN1A-related epilepsies.
Gallagher D, Pérez-Palma E, Bruenger T, et al.
Epilepsia 2024; (65(4)):1046-1059 doi:10.1111/epi.17882.
PMID: 38410936 - 14
Phenotypic and Genotypic Characteristics of SCN1A Associated Seizure Diseases.
Chen C, Fang F, Wang X, et al.
Frontiers in molecular neuroscience 2022; (15()):821012 doi:10.3389/fnmol.2022.821012.
PMID: 35571373 - 15
Severe communication delays are independent of seizure burden and persist despite contemporary treatments in SCN1A+ Dravet syndrome: Insights from the ENVISION natural history study.
Perry MS, Scheffer IE, Sullivan J, et al.
Epilepsia 2024; (65(2)):322-337 doi:10.1111/epi.17850.
PMID: 38049202 - 16
Dravet syndrome: Advances in etiology, clinical presentation, and treatment.
He Z, Li Y, Zhao X, Li B
Epilepsy research 2022; (188()):107041 doi:10.1016/j.eplepsyres.2022.107041.
PMID: 36368227 - 17
SCN1A-related phenotypes: Epilepsy and beyond.
Scheffer IE, Nabbout R
Epilepsia 2019; (60 Suppl 3()):S17-S24 doi:10.1111/epi.16386.
PMID: 31904117
This page explains how GEFS+ seizure patterns may differ from Dravet syndrome for educational purposes and is not medical advice. A pediatric neurologist or epilepsy specialist should interpret your child’s seizures, development, and genetic results.